Investor Relations

Oct 5 2011 3:41 PM

Founded by some of the world's most renowned specialists in cancer diagnosis, treatment and research, Champions Oncology (OCTBB:CSBR) is engaged in the development of advanced technologies to enhance the personalized treatment of human cancers. Based on the proprietary Champions Personalized TumorGraft™ technology, Champions offers cancer patients and their physicians—as well as cancer researchers—powerful tools to more effectively guide cancer treatments for patients and the development of new cancer drugs.

Download XBRL files:

Please contact Susan Foreman at Champions Oncology, Inc., for investor information or to arrange to communicate with Company principals..

Susan Foreman
Champions Oncology, Inc.
E-mail: [email protected]
Phone: 410.369.0365

Quarterly Updates

Corporate Governance

Charters:

 

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.